Ryan Martins - Feb 3, 2023 Form 4 Insider Report for 89bio, Inc. (ETNB)

Role
Chief Financial Officer
Signature
/s/ Ryan A. Murr, as attorney-in-fact for Ryan Martins
Stock symbol
ETNB
Transactions as of
Feb 3, 2023
Transactions value $
-$45,356
Form type
4
Date filed
2/7/2023, 06:36 PM
Previous filing
Feb 3, 2023
Next filing
Feb 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETNB Common Stock Options Exercise $9.33K +3K +8.34% $3.11* 39K Feb 3, 2023 Direct
transaction ETNB Common Stock Sale -$39.3K -3K -7.15% $13.11 39K Feb 3, 2023 Direct F1
transaction ETNB Common Stock Sale -$7.52K -592 -1.65% $12.70 35.4K Feb 3, 2023 Direct F1
transaction ETNB Common Stock Tax liability -$7.84K -592 -1.69% $13.24 34.3K Feb 5, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETNB Stock Option (Right to Buy) Options Exercise $0 -3K -3.53% $0.00 81.9K Feb 3, 2023 Common Stock 3K $3.11 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 2,500 performance stock units on February 5, 2023.
F3 This option represents a right to purchase a total of 94,901 shares of the Issuer's common stock, one quarter of which vested on July 21, 2020, with the remaining three quarters vesting in equal quarterly installments over the following three years.